key: cord-1037406-nkz8ir6i
authors: Vlaar, Alexander P J; de Bruin, Sanne; Brouwer, Matthijs C; van de Beek, Diederik
title: Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
date: 2020-12-14
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30424-0
sha: 9ebae50de5c7ed2427cfc2a39865f3c42211959d
doc_id: 1037406
cord_uid: nkz8ir6i

nan

Authors' reply

We thank Dimitrios C Mastellos and col leagues for their interest in our exploratory, phase 2 randomised controlled trial 1 in 30 patients with severe COVID-19. The authors offer their interpretation of the inefficacy of IFX-1, arguing that upstream inhibition of the complement cascade could be superior to inhibiting C5a. We are surprised that the authors avoid discussing the efficacy signals and group differences generated in our study, and instead argue based on uncontrolled observational data relating to upstream complement C3 inhibitors. We do not think their conclusion is substantiated. As stated by regu latory bodies like the US Food and Drug Administration, in phase 2 studies, researchers administer the drug to a group of patients with the disease or condition for which the drug is being developed to refine research questions and design new phase 3 research protocols. Typically, as in our study, these trials are not large enough to show that the drug is beneficial, but rather suggest efficacy trends and concepts.

In COVID-19, the secondary induction of a systemic hyperinflammatory state with immunothrombosis and endothelial damage in the lungs and other organs, including the kidney, appears to be a main driver of morbidity and mortality. Accumulating evidence points towards a key role for C5a-induced neutrophil activation in disease pathogenesis in critically ill patients with COVID-19. 2 C5a can be produced by conventional complement activation cascades, but also through direct enzymatic cleavage via proteinases, especially those of the coagulation pathways such as thrombin and plasmin. Because a hyper coagulable state is often observed in patients with severe COVID-19, a large pro por tion of C5a generated by this enzymatic activation can be expected. C5a made via these enzymes would not be blocked by upstream blockers such as the C5 inhibitor eculizumab. 3 There fore, a targeted blockade of C5a might offer tighter control of C5a in COVID-19 than might an upstream block ade. Thromboinflammation driven by neutrophil extracellular traps has been shown to be a C5a-C5aRdependent process in This study provides support to our hypothesis that C5a induces the release of tissue factor by neutrophils, the link between C5a and coagulation, and a potential positive feedback loop for more C5a generation. 1 The observed increase in D-dimer concentrations early after C5a inhibition with IFX-1 should be seen within the context of thromboinflammation driven by neutrophil extracellular traps, C5a generation, and coagulation.

The exploratory phase 2 part of the PANAMO trial showed that C5a inhibition with IFX-1 was safe in patients with severe COVID-19. 1 The observed favourable effects of IFX-1 on mortality, kidney function, lactate dehydrogenase concentra tions (a marker of tissue damage), and lymphocytopenia are preliminary because the study was not powered on these endpoints, but they do support investigating C5a inhibition with IFX-1 in a phase 3 trial using 28-day mortality as the primary endpoint. The phase 3 part of the PANAMO trial has been initiated (NCT04333420). Importantly, the effects of the C5a inhibitor IFX-1 do not automatically apply to other C5a inhibitors or inhibitors blocking other complement factors in upstream activation pathways. Conclusions on the potential superiority of treatment approaches from very small, noncontrolled studies-such as the three patients treated with AMY-101should be avoided or handled with care. To our knowledge, our data are the first published data of a complement inhib i tor from a random ised controlled clinical trial in patients with COVID-19.

The declaration of interests remains the same as in the original Article.

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis